Rhenman & Partners Asset Management AB Has $1.27 Million Stock Holdings in Janux Therapeutics, Inc. $JANX

Rhenman & Partners Asset Management AB decreased its stake in Janux Therapeutics, Inc. (NASDAQ:JANX) by 61.1% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 55,127 shares of the company’s stock after selling 86,500 shares during the quarter. Rhenman & Partners Asset Management AB owned 0.09% of Janux Therapeutics worth $1,273,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. US Bancorp DE lifted its stake in Janux Therapeutics by 2,402.9% during the first quarter. US Bancorp DE now owns 1,727 shares of the company’s stock valued at $47,000 after buying an additional 1,658 shares in the last quarter. Ameritas Investment Partners Inc. raised its holdings in shares of Janux Therapeutics by 25.6% during the second quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock valued at $93,000 after acquiring an additional 820 shares during the period. FNY Investment Advisers LLC lifted its position in shares of Janux Therapeutics by 111.8% in the 2nd quarter. FNY Investment Advisers LLC now owns 5,210 shares of the company’s stock valued at $120,000 after acquiring an additional 2,750 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Janux Therapeutics by 26.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,125 shares of the company’s stock valued at $192,000 after acquiring an additional 1,488 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey boosted its stake in Janux Therapeutics by 29.5% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,054 shares of the company’s stock worth $209,000 after purchasing an additional 2,060 shares during the period. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Trading Up 10.2%

Janux Therapeutics stock opened at $34.74 on Wednesday. The company has a market capitalization of $2.09 billion, a P/E ratio of -20.68 and a beta of 2.83. Janux Therapeutics, Inc. has a 1-year low of $21.73 and a 1-year high of $71.71. The firm’s fifty day simple moving average is $26.43 and its 200-day simple moving average is $25.14.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.21. The firm had revenue of $10.00 million during the quarter, compared to the consensus estimate of $3.07 million. On average, equities research analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Wolfe Research initiated coverage on Janux Therapeutics in a research report on Tuesday, November 18th. They set a “peer perform” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Janux Therapeutics in a research report on Tuesday. Guggenheim initiated coverage on shares of Janux Therapeutics in a research note on Wednesday, September 3rd. They set a “buy” rating and a $72.00 target price for the company. Finally, Piper Sandler assumed coverage on shares of Janux Therapeutics in a research note on Monday, August 18th. They issued an “overweight” rating and a $42.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $79.17.

Insiders Place Their Bets

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 16,665 shares of the company’s stock in a transaction dated Tuesday, October 28th. The shares were sold at an average price of $30.06, for a total transaction of $500,949.90. Following the completion of the sale, the insider directly owned 82,139 shares in the company, valued at $2,469,098.34. This represents a 16.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 29.40% of the stock is currently owned by corporate insiders.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.